Skip to main content
. 2022 Apr 25;13:834113. doi: 10.3389/fphar.2022.834113

TABLE 3.

Survival outcome of PFS.

Study CAR T Median Progression-free Survival, months Median Follow-Up, months
Locke et al. (2019) axi-cel 5.9 (3.3–15.0) 27.1
Abramson et al. (2020) liso-cel 6.8 (3.3–12.7) 23.9
Ying et al. (2021) relma-cel 7.0 (4.8-NR) 17.9
Nastoupil et al. (2020) axi-cel 8.3 (6.0–15.1) 12.9
Iacoboni et al. (2021) tisa-cel 3.0 (2.6–4.7) 14.1
Grana et al. (2021) axi-cel 5.8 6.0

CAR T: chimeric antigen receptor T cells; NR: not reached.